US weight loss drugmakers slash prices in fight to win customers

Competition in the U.S. weight-loss drug market is intensifying, with prices declining as more manufacturers enter a space once dominated by Ozempic and Wegovy. The price drops reflect increased supply and competition from GLP-1 agonists, a class of drugs originally developed for diabetes treatment that have become blockbuster medications for weight management. Lower prices could expand access to treatments previously limited by cost, but the sustainability of price competition in this market remains uncertain. Manufacturers are betting on volume and market share gains, even at reduced margins, while insurers and patients benefit from negotiating power they lacked when options were scarce. The outcome will likely depend on whether competition can hold as the market consolidates and demand stabilizes.